Shire Plc Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 7/20/2026)
| Balance Sheet | Total Assets | 50,153,115,324.80 | ROE | – |
| Balance Sheet | Total Equity | 26,777,481,868.80 | ROA | – |
| Cashflow | Capital Expenditures | -641,194,363.60 | P/FCF | – |
| Cashflow | Free Cash Flow | 2,509,580,922.80 | – | – |
| Cashflow | Operating Cash Flow | 3,150,775,286.40 | P/CF | – |
| Income | Earnings per Share (diluted) | 4.95 | Div. Yield | – |
| Income | Net Income | 3,161,730,128.00 | P/E | – |
| Income | Shares Outstanding | 917,100,000.00 | P/B | – |
| Income | Total Revenue | 10,694,960,188.80 | P/S | – |
Ratios calculated on: –
Company Description
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.shire.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more